From Wikipedia, the free encyclopedia
Neurokinin NK1 antagonists are a novel class of medications that possesses unique antidepressant[1], anxiolytic[2], and antiemetic properties.
The NK2 and NK3 receptors are also targets for novel classes of medications, and also show prominent antidepressive and anxiolytic effects.[3]
[edit] References
Antidepressants (ATC N06A) |
Monoamine oxidase inhibitors (MAOI) |
Harmaline, Iproniazid, Isocarboxazid, Nialamide, Pargyline, Phenelzine, Selegiline, Toloxatone, Tranylcypromine
RIMAs: Brofaromine, Moclobemide |
Dopamine reuptake inhibitor (DARI) |
Amineptine, Phenmetrazine, Vanoxerine |
Norepinephrine-dopamine reuptake inhibitors (NDRI) |
Bupropion |
Norepinephrine reuptake inhibitor (NRI) or (NARI) |
Atomoxetine, Maprotiline, Reboxetine, Viloxazine |
Serotonin-norepinephrine reuptake inhibitor (SNRI) |
Duloxetine, Milnacipran, Nefazodone , Venlafaxine |
Selective serotonin reuptake inhibitor (SSRI) |
Alaproclate, Citalopram, Escitalopram, Etoperidone, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Zimelidine |
Selective serotonin reuptake enhancer (SSRE) |
Tianeptine |
Noradrenergic and specific serotonergic antidepressant (NaSSA) |
Mirtazapine |
Tricyclic antidepressants (TCA) |
Amitriptyline, Amoxapine, Butriptyline, Clomipramine, Desipramine, Dibenzepin, Dothiepin, Doxepin, Imipramine, Iprindole, Lofepramine, Melitracen, Nortriptyline, Opipramol, Protriptyline, Trimipramine |
Tetracyclic antidepressants |
Maprotiline, Mianserin, Nefazodone, Trazodone |